OS in different populations and according to baseline mutations and risk scores. OS shown in (A) all patients in the prior systemic therapy pooled efficacy population and prior systemic therapy pooled safety population; (B) S/A/R⁻ (0 mutations at baseline) and S/A/R⁺ (≥1 mutation at baseline) patients in the prior systemic therapy pooled safety population; and (C) low, intermediate, and high MARS categories in prior systemic therapy pooled safety population.